Site of lymphoma and CNS relapse in non-GCB and GCB DLBCL by dual expresser status
| . | Non-GCB DLBCL (n = 185) . | GCB DLBCL (n = 241) . | ||
|---|---|---|---|---|
| MYC+BCL2+ (n = 75) No. (%) . | Non-MYC+BCL2+ (n = 110) No. (%) . | MYC+BCL2+ (n = 52) No. (%) . | Non-MYC+BCL2+ (n = 189) No. (%) . | |
| Any lymphoma relapse | 42 (56) | 37 (34) | 19 (36.5) | 41 (22) |
| Site of lymphoma relapse | ||||
| Systemic only | 30 (71) | 29 (78) | 16 (84) | 34 (83) |
| CNS + systemic | 0 | 1 (3) | 0 | 0 |
| CNS only | 9 (22) | 2 (5.5) | 2 (11) | 2 (7) |
| Unknown | 3 (7) | 5 (13.5) | 1 (5) | 4 (10) |
| Total CNS relapse | 9 | 3 | 2 | 3 |
| Site of CNS relapse | ||||
| Parenchymal only | 7 | 2 | 2 | 2 |
| Parenchmyal and leptomeningeal | 1 | 1 | 0 | 0 |
| Lepotomeningeal only | 1 | 1 | 0 | 1 |
| . | Non-GCB DLBCL (n = 185) . | GCB DLBCL (n = 241) . | ||
|---|---|---|---|---|
| MYC+BCL2+ (n = 75) No. (%) . | Non-MYC+BCL2+ (n = 110) No. (%) . | MYC+BCL2+ (n = 52) No. (%) . | Non-MYC+BCL2+ (n = 189) No. (%) . | |
| Any lymphoma relapse | 42 (56) | 37 (34) | 19 (36.5) | 41 (22) |
| Site of lymphoma relapse | ||||
| Systemic only | 30 (71) | 29 (78) | 16 (84) | 34 (83) |
| CNS + systemic | 0 | 1 (3) | 0 | 0 |
| CNS only | 9 (22) | 2 (5.5) | 2 (11) | 2 (7) |
| Unknown | 3 (7) | 5 (13.5) | 1 (5) | 4 (10) |
| Total CNS relapse | 9 | 3 | 2 | 3 |
| Site of CNS relapse | ||||
| Parenchymal only | 7 | 2 | 2 | 2 |
| Parenchmyal and leptomeningeal | 1 | 1 | 0 | 0 |
| Lepotomeningeal only | 1 | 1 | 0 | 1 |
Dual expresser status is provided in terms of MYC+BCL2+ vs non-MYC+BCL2+.